Followers | 195 |
Posts | 20025 |
Boards Moderated | 0 |
Alias Born | 09/18/2017 |
Saturday, May 25, 2019 12:02:57 AM
Recent OTLK News
- Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series • GlobeNewswire Inc. • 09/16/2024 12:05:00 PM
- Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series • GlobeNewswire Inc. • 09/13/2024 01:05:00 PM
- Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial • GlobeNewswire Inc. • 09/04/2024 12:35:00 PM
- Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 12:45:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2024 08:55:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:15:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:48:51 AM
- Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update • GlobeNewswire Inc. • 08/14/2024 11:05:00 AM
- Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference • GlobeNewswire Inc. • 08/12/2024 01:05:00 PM
- Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast • GlobeNewswire Inc. • 08/07/2024 12:35:00 PM
- Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024 • GlobeNewswire Inc. • 07/30/2024 01:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 12:41:41 PM
- Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD • GlobeNewswire Inc. • 07/08/2024 12:35:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/14/2024 08:10:50 PM
- Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference • GlobeNewswire Inc. • 06/11/2024 01:05:00 PM
- Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD • GlobeNewswire Inc. • 05/28/2024 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:19:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:15:37 PM
- Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update • GlobeNewswire Inc. • 05/15/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:05:33 PM
- Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD • GlobeNewswire Inc. • 05/13/2024 12:50:00 PM
- Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast • GlobeNewswire Inc. • 05/09/2024 12:45:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/07/2024 04:15:34 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 08:09:46 PM
- Outlook Therapeutics® to Present at the Retina World Congress 2024 • GlobeNewswire Inc. • 05/02/2024 01:05:00 PM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM